iTeos meldet Finanzergebnisse für das erste Quartal 2024 und gibt aktuelle Geschäftsinformationen bekannt
May 11, 2024 13:31 ET
|
iTeos Therapeutics Inc.
- Belrestotug + Dostarlimab übertraf die vordefinierten Wirksamkeitskriterien für klinisch relevante Aktivität, die in einer Zwischenbewertung der Phase 2 von GALAXIES Lung-201 beobachtet wurde -...
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
May 10, 2024 08:26 ET
|
iTeos Therapeutics Inc.
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...
UTR Sports Selects Sportradar in Long Term, Wide-ranging Partnership
May 09, 2024 08:30 ET
|
UTR Sports
Palo Alto, Calif. and St. Gallen, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- UTR Sports today announced a long-term partnership with Sportradar (NASDAQ: SRAD) to transform fan and bettor...
Sportradar to Participate in the J.P. Morgan Global Technology, Media and Communications Conference on May 21
May 09, 2024 08:00 ET
|
Sportradar AG
ST. GALLEN, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company, today announced that Carsten...
Australia Rail Signalling Market 2024-2030 - Size, Trends, Segmentation, Revenue, Outlook, Companies, Share, Growth, Analysis, Value, Industry & Forecast
May 08, 2024 06:05 ET
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Australia Rail Signalling Market 2024-2030 Size, Trends, Segmentation, Revenue, Outlook, Companies, Share, Growth, Analysis, Value, Industry &...
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 07, 2024 08:30 ET
|
Inozyme Pharma Inc.
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
Esperion Reports First Quarter 2024 Financial Results
May 07, 2024 06:00 ET
|
Esperion Therapeutics, Inc.
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43%...
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
May 07, 2024 04:09 ET
|
AKAMPION
Geneva (Switzerland), May 7, 2024 – Atopia Therapeutics, a leader in the development of breakthrough asthma and allergy therapies, today announced the appointment of Dr. Grégoire Chevalier as Chief...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET
|
Corvus Pharmaceuticals, Inc.
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell...
Sportradar Appoints Behshad Behzadi as Company’s Chief Technology Officer and Chief Artificial Intelligence Officer
May 01, 2024 03:30 ET
|
Sportradar AG
ST. GALLEN, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”) today announced that Behshad Behzadi has been named Chief Technology...